Latvian Institute of Organic Synthesis has identified subtilisin-like protease 1 (PfSUB1) (Plasmodium falciparum) inhibitors reported to be useful for the treatment of malaria.

Idorsia Pharmaceuticals Ltd. has synthesized aryl sulfone and sulfanone derivatives acting as orexin OX2 receptor agonists reported to be useful for the treatment of eating disorders, fatigue, Kleine-Levin syndrome, narcolepsy, obesity, pain, and psychiatric and inflammatory disorders, among others.

Eli Lilly & Co. and Evotec International GmbH have disclosed Rho-associated protein kinase 2 (ROCK2) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis, and inflammatory and neurological disorders.

Grünenthal GmbH has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Acurex Biosciences Corp. has divulged fused quinone compounds acting as ferroptosis inhibitors reported to be useful for the treatment of mitochondrial disease.

Deciphera Pharmaceuticals LLC has identified phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3; Vps34) inhibitors reported to be useful for the treatment of cancer.

Alterome Therapeutics Inc. has synthesized RAC-α serine/threonine-protein kinase (AKT1; PKB α) (E17K mutant) inhibitors reported to be useful for the treatment of cancer.

Beijing Konruns Pharmaceutical Co. Ltd. has disclosed tyrosine-protein kinase yes (YES1) inhibitors reported to be useful for the treatment of cancer.

Design Therapeutics Inc. has described transcription modulators reported to be useful for the treatment of myotonic dystrophy type 1 (DM1) and Fuchs’ dystrophy.

Ensem Therapeutics has divulged compounds acting as cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.